Ipsen to present elafibranor data from phase II ELMWOOD clinical study at EASL Congress 2025 on May 10, 2025

Join Pharma | Login

	Editorial


	MINISTRY OF PHARMACEUTICALS
	Wednesday, April 23, 2025
	Ever since the Narendra Modi-led BJP government came to power in the year 2014, there have been renewed talk of an exclusive Union ministry for pharmaceuticals and medical devices. There can be no two opinions
	Past Editorial...

TODAY'S NEWS


18:00 [IST]	Ipsen to present elafibranor data from phase II ELMWOOD clinical study at EASL Congress 2025 on May 10, 2025
17:00 [IST]	Orion & Criceto signs agreement to develop and commercialise Aporon, an innovative apomorphine spray to treat OFF episodes in Parkinson’s disease
16:45 [IST]	Medanta to invest Rs. 500 crore for healthcare in North East with a 400-bed super specialty hospital in Guwahati
16:00 [IST]	EMA grants conditional marketing authorization to Italfarmaco’s Duvyzat to treat Duchenne muscular dystrophy
15:00 [IST]	Keymed Biosciences’ CM518D1, a CDH17-targeted ADC receives IND approval from China NMPA to treat solid tumours
14:30 [IST]	Fortis’ Robot-Assisted Bilateral Knee Replacement with VELYS equips patient to regain mobility after 5 years

more news >>

TOP NEWS


08:00 [IST]	PCI to initiate new assessment and rating system for pharmacy institutions
08:00 [IST]	NABL issues updated accreditation criteria for biobanks aligned with ISO 20387:2018
08:00 [IST]	Hyderabad tops student pass outs among the six NIPERs launched in 2007
08:00 [IST]	Health informatics and medical AI are making waves in job market
08:00 [IST]	Kerala IPA initiates training programmes for B Pharm students to make them industry professionals
08:00 [IST]	Ayush and herbal products exports report growth of 6% in first 11 months of FY25

more news >>

YESTERDAY'S NEWS


18:00 [IST]	Zealand Pharma begins patient enrolment in phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes
17:00 [IST]	Debiopharm, Oncodesign Services announce license agreement for use of AbYlink technology for pre-clinical services
16:00 [IST]	Bioxodes announces positive data from BIRCH phase 2a trial of BIOX-101 to treat patients with intracerebral hemorrhagic stroke
15:00 [IST]	Basilea Pharmaceutica receives CHF 1.7 mn milestone payment from Asahi Kasei Pharma for strong sales of Cresemba in Japan
14:00 [IST]	BioNTech to present clinical & pre-clinical data from mRNA and next-generation immuno-oncology priority programmes at AACR 2025
13:00 [IST]	Evotec announces progress in strategic protein degradation research collaboration with Bristol Myers Squibb

more news >>

INTERVIEW


All DIs in TN are fully competent to inspect manufacturing units as per Revised Schedule M: MN Sridhar
MN Sridhar, director of the Tamil Nadu Drugs Control Department

Past Interviews...

	What's New?

Syngene’s revenue from operations crossed Rs. 1,000 crore mark in Q4, PAT dips by 3%, full year earnings up 4% to Rs. 3,642 crore Methotrexate 2.5 Mg Tab/cap Fluvoxamine 100mg Tab Vitamin D3 Inj -600000 Iu-1 Ml. Tab Tianeptine 12.5 Mg

Opinion Poll

Will the introduction of Revised Schedule M by Union Health Ministry solve the issue of quality of Indian drugs?

YesNoCan't Say

View Past Poll

Corporate

Special Features

Features

Chronicle Pharmabiz Specials

Forthcoming Events

TENDERS & PROJECTS

	Tenders & Enquiries
	Pharma Projects

CORPORATE

	Company Profile
	Corporate Results
	Corporate X-ray
	Pharmabiz Studies of Top Companies

US FDA UPDATE

EXPORT & IMPORT

	Drug Export Procedures
	Drug Units With WHO GMP Certification
	Pharma Export Data
	Import Reg. Update

PHARMA LAWS & DOCUMENTS

LIST OF LABS & GOVT. BODIES

	Govt Recognised In-House R&D Units
	AICTE Boards & Committees
	List of Indian CROs
	List of CROs (International)
	Govt & approved labs of India
	List of State Drugs Controllers